Helix BioPharma Corp. collaborator ProMab Biotechnologies to present at the CAR-TCR Summit 2018 in Boston
RICHMOND HILL, Ontario, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP), (FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that its collaborator ProMab Biotechnologies, Inc. (“ProMab”) will present at the CAR-TCR Summit 2018 being held from September 4th - 7th, 2018 in Boston, Massachusetts.
Dr. Vita Golubovskaya, Director, R&D, BD of Promab Biotechnologies will present on September 5th at 12:25pm. The title of the presentation is “Novel CAR-T Cells Against Solid and Hematological Cancers”. Dr. Golubovskaya’s presentation will include certain preclinical data from the multiple myeloma project currently in collaboration with Helix.
Helix continues to aim for a possible first-in-human CAR-T study in 2019. To achieve this goal, Helix’s wholly-owned Polish subsidiary Helix Immuno-Oncology (“HIO”) will be leading the preclinical and clinical development program in Poland prioritizing a possible European clinical submission. Helix and HIO are engaging experts to advise on the program and are currently securing the necessary financial resources to meet the project timelines.
About Helix BioPharma Corp.
Helix BioPharma Corp. is an immuno-oncology company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix’s product development initiatives include its novel L-DOS47 new drug candidate and Chimeric Antigen Receptor (“CAR”) based cell therapies. Helix is currently listed on the TSX and FSE under the symbol “HBP”.
About Helix Immuno-Oncology S.A.
Helix Immuno-Oncology S.A. is a wholly-owned subsidiary of Helix BioPharma Corp., a research company specializing in the development of novel anti-tumour therapies in the field of immune-oncology. The company’s development initiatives include V-DOS47 drug candidate for Triple Negative Breast Cancer treatment, cellular therapies as well as combination of thereof.
About ProMab Biotechnologies
ProMab Biotechnologies is a US biotechnology company that develops and commercializes recombinant proteins, custom monoclonal antibodies, CAR-T products through the integration of bioinformatics, gene cloning, protein expression and purification, and immunology, using novel high-throughput technologies.
Investor Relations
Helix BioPharma Corp.
9120 Leslie Street, Suite 205
Richmond Hill, Ontario, L4B 3J9
Tel: 905-841-2300
Email:
Cautionary Statements
This news release may contain forward-looking statements and information (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws. Forward-looking statements are statements and information that are not historical facts but instead include financial projections and estimates; statements regarding plans, goals, objectives, intentions and expectations with respect to Helix’s future business, operations, research and development, including Helix’s activities relating to its drug development program, the anticipated timelines for the commencement or completion of certain activities, including enrolment of patients, the expansion of the DOS47 platform into other compounds and indications and other information in future periods. Forward-looking statements, which may be identified by words including, without limitation, “may”, “improve”, “planned”, “possible”, “postulated”, “enhances”, “potential”, “development”, “unique”, “expects”, “plans”, “will”, “intends”, “pending”, “objective”, “exploring”, “projected”, and other similar expressions, are intended to provide information about management’s current plans and expectations regarding future operations.
Although Helix believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties that may cause actual results or events to differ materially from those anticipated and no assurance can be given that these expectations will be realized, and undue reliance should not be placed on such statements. Risk factors that could cause actual results or events to differ materially from the forward-looking statements include, without limitation: (i) Helix’s ability to operate as a going concern being dependent mainly on securing sufficient additional financing in order to fund its ongoing research and development and other operating activities; (ii) the generally inherent uncertainty involved in scientific research and drug development and those specific to Helix’s pre-clinical and clinical development programs (DOS47, L-DOS47, V-DOS47 and CAR-T); (iii) difficulties in predicting accurate timelines for the commencement or completion of certain activities including those in support of ongoing clinical trials; (iv) positive preliminary results from early-stage clinical trials may not be indicative of the final results from the trial or be indicative of favorable outcomes in later-stage clinical trials; (v) delays or inability to complete clinical trials successfully and the long lead-times and high costs associated with obtaining regulatory approval to market any product which may result from successful completion of such trials; (vi) clinical data may not demonstrate adequate efficacy and safety to result in regulatory approval to market any of Helix’s product candidates in any jurisdiction; (vii) economic and market conditions may become worse and market shifts may require a change in strategic focus; and (viii) those risks and uncertainties affecting Helix as more fully described in Helix’s most recent Annual Information Form, including under the headings “Forward-Looking Statements” and “Risk Factors”, filed under Helix’s profile on SEDAR at (together, the “Helix Risk Factors”). Certain material factors and assumptions are applied in making the forward-looking statements, including, without limitation, that sufficient financing will be obtained in a timely manner to allow Helix to continue operations and implement its clinical trials in the manner and on the timelines anticipated and that the Helix Risk Factors will not cause Helix’s actual results or events to differ materially from the forward-looking statements. These cautionary statements qualify all such forward-looking statements.
Forward-looking statements and information are based on the beliefs, assumptions, opinions, plans and expectations of Helix’s management on the date of this news release, and the Company does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions, plans or expectations, or other circumstances change, except as required by law.
